RTW Biotech Opp. - RTW Biotech to acquire Arix Bioscience's assets
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM,
THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL, OR THE SOLICITATION OF AN OFFER TO ACQUIRE, ANY SECURITIES IN
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 AS AMENDED AND TRANSPOSED INTO
FOR IMMEDIATE RELEASE
Legal Entity Identifier: 549300Q7EXQQH6KF7Z84
1
RTW Biotech Opportunities Ltd / Arix Bioscience PLC
RTW Biotech Opportunities Limited ("RTW Bio") to acquire Arix Bioscience plc's ("Arix") assets, unlocking value and accelerating growth for all shareholders
Highlights
· Transaction delivers a scaled pro-forma RTW Bio with an expected pro-forma net asset value ("NAV") of approximately
· Enhanced RTW Bio profile provides increased liquidity potential, a more efficient cost base, and re-rating opportunity
· Arix shareholders to receive new RTW Bio shares at an implied premium of approximately 46 per cent to Arix's pre-strategic review share price and future upside potential from management by RTW Investments, LP's superior capabilities, deal access, and life sciences investing platform
· Expected to be immediately accretive to RTW Bio NAV per share at completion
Transaction Summary
Proposed scheme of reconstruction
The boards of RTW Bio and Arix are pleased to announce they have agreed to the terms of a recommended all-share acquisition of Arix's assets by RTW Bio, via a subsidiary, to be effected through a scheme of reconstruction and the voluntary winding-up of Arix under section 110 of the Insolvency Act 1986 (the "Scheme"). The Scheme is conditional upon regulatory and Arix shareholder approval.
The Scheme will combine the assets of Arix with RTW Bio, enhancing RTW Bio's position as a leading
Under the proposed terms of the Scheme, each eligible holder of ordinary shares in Arix (an "Arix Share") at the Scheme record time will receive:
1.4633 new RTW Bio shares ("New RTW Bio Shares") in exchange for each Arix Share
Based on the volume weighted average price of
The proposed terms of the Scheme represent a premium of approximately 46 per cent to the closing price of
Acquisition of a 25.5 per cent interest in Arix from Arix's largest shareholder
RTW BIO, via its subsidiary RTW Biotech Opportunities Operating Ltd ("RTW OpCo"), today expects to enter into an agreement to acquire 33,023,210 Arix shares from Arix's largest shareholder, Acacia Research Corporation ("Acacia"), representing an approximately 25.5 per cent interest in Arix (the "Acacia Stake") for
Immediately following completion of the Share Purchase and Scheme, the eligible holders of ordinary shares in Arix ("Arix Shareholders"), excluding the holders of the Acacia Stake, are expected to hold approximately 38.8 per cent and existing RTW Bio shareholders are expected to hold approximately 61.2 per cent of the pro-forma company.
Background to and strategic rationale of the Scheme
Since the Arix announcement on
Benefits of the Scheme
The boards of RTW Bio and Arix believe the Scheme has clear strategic rationale and offers compelling benefits to shareholders of both companies:
· RTW is a best-in-class manager with superior capabilities: RTW is a leading, specialised life science investor with a record of over 14 years of success, including delivering an annualised net return of 21.6 per cent since inception from its leading private fund. RTW's capabilities are underpinned by a science-led investment approach and its full lifecycle strategy of investing and supporting growth companies across different stages of development, business inflection points and capital structures. A team of 43 investment professionals, the majority of whom have advanced scientific degrees, drive RTW's science-led approach, which is focused on solving the most challenging unmet patient needs by identifying, investing in, supporting, and building innovative life science companies. This long-term approach to investing enables RTW to maximise value capture from the opportunities it participates in. RTW's infrastructure and scale provide superior access to the most exciting life science companies and events. In 2022, RTW had access to more than 200 medical meetings and 200 deals from syndicate and partner investors alone. RTW intends to utilise its sophisticated infrastructure and science and research-led investment process to manage the assets of RTW Bio and Arix following completion of the Scheme. Compared to Arix's focus on life science private and venture capital investing, RTW is able to offer a greatly enhanced investment offering with a scaled equity investing platform, company creation, royalty and structured financing as well as alternative vehicles that provides a wider opportunity for returns.
· An enhanced return potential from deployment of new capital: RTW Bio has a track record of successfully deploying capital and generating returns. Through 2022 and year-to-date 2023, RTW Bio made 9 new investments and had 7 successful IPOs or exits of portfolio companies. The Scheme enables RTW to access Arix's assets which comprise approximately
· Immediate scale and complementary portfolio benefits: The Scheme delivers a meaningful and immediate increase in NAV such that the combined NAV of the RTW Bio and Arix portfolio is expected to be approximately
· Compelling value creation today and in the future for all shareholders: The Scheme is expected to deliver value for both RTW Bio and Arix shareholders both immediately at completion as well as in the future. The terms of the Scheme imply an offer price of
· Enhanced profile provides liquidity and re-rating opportunity: The Scheme further establishes RTW Bio as a leading
· Unique opportunity to buy into a depressed market while innovation is booming: The board of RTW Bio believes there are currently significant tailwinds that make now a compelling time to be deploying capital into the life science sector. The RTW Bio board believes this is a golden age of innovation with genetic information and new modalities accelerating the number of new treatments and corresponding number of new investment opportunities. Despite this, in part due to macro-economic conditions, life science remains out of favour relative to the other parts of the market, which means now is a unique time to invest in the right assets at depressed valuations. Further, shifting needs of the largest pharmaceutical companies are pushing M&A strategies to be earlier and across smaller transaction sizes, which means RTW Bio's science-led strategy, which seeks to invest in innovation, is well positioned to benefit from these tailwinds in the future.
Commenting on the Scheme:
"Acquiring Arix's complementary life science assets is a step-change accelerator to our vision for RTW Bio to be a
"I am delighted that we have reached an agreement to bring Arix's cash and life science assets into RTW Bio and we welcome Arix shareholders to the RTW Bio shareholder registry. The combination has compelling strategic rationale which is expected to generate future growth opportunities for all shareholders. The transaction represents an exciting opportunity to build upon our strong foundation by adding capital and scale to our best-in-class platform".
Peregrine Moncreiffe, Chairman of the Board of Arix, stated:
"Having considered the full spectrum of options available, the Special Committee of the Arix Board, together with its financial adviser, determined that this combination provides the best outcome for Arix shareholders and accordingly unanimously recommends shareholders vote in favour of the Scheme. The clear strategic and financial logic of the transaction maximizes the value of our assets and provides a meaningful long term growth opportunity with RTW and their impressive track record as a life sciences investment manager. We look forward to being long-term shareholders in the combined RTW Bio."
About RTW Biotech Opportunities Ltd
RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
As at
About RTW Investments, LP
RTW Investments, LP is a
About Arix Bioscience plc
Arix is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life science.
Arix collaborates with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, Arix is able to bring this exciting growth phase of our industry to a broader range of investors.
As at
Further details on the Scheme
The Scheme will be effected by way of a scheme of reconstruction under section 110 of the Insolvency Act 1986, pursuant to which RTW OpCo shall acquire the assets of Arix in exchange for issuing New RTW Bio Shares to eligible Arix Shareholders.
The Scheme will be conditional on:
· RTW OpCo's entry into the share purchase agreement with Acacia within one business day following the date of this Announcement;
· approval of the Scheme by the Arix Shareholders;
· any Arix Shareholders who exercise dissenter rights pursuant to Section 111 of the Insolvency Act 1986 during the dissenting period (as set out in such act), holding in aggregate no more than 2 per cent of the Arix Shares (as at the date of the first shareholder meeting);
· approval from the Financial Conduct Authority ("FCA") of the prospectus to be published by RTW Bio with respect to the issuance of New RTW Bio Shares;
· approval from the FCA and the London Stock Exchange, respectively, for the admission to listing and trading on the London Stock Exchange; and
· approval from the FCA for the change in control.
In connection with the Scheme, Arix will convene two shareholder meetings. The first meeting will be convened to approve the Scheme; and the second meeting will be convened to approve the winding-up of Arix and the appointment of the liquidator.
In accordance with customary practice for schemes of reconstruction undertaken pursuant to section 110 of the Insolvency Act 1986, the City Code on Takeovers and Mergers does not apply to the Scheme.
Co-operation Agreement
Arix, RTW Bio and RTW OpCo have also today entered into a co-operation agreement pursuant to which they have given certain reciprocal undertakings in relation to the conduct of the Scheme and the satisfaction of the conditions (listed above). Pursuant to the co-operation agreement, Arix has undertaken not to solicit a competing proposal and to pay a break fee equivalent to 1 per cent of its market capitalisation (as at the date of the co-operation agreement) to RTW OpCo in certain circumstances, including if the Special Committee of Arix directors withdraws its recommendation or recommends a competing proposal.
Irrevocable undertakings
Arix has received irrevocable undertakings from certain Arix directors, RTW OpCo and Acacia to vote in favour of the Scheme.
Arix directors Peregrine Moncreiffe and
Acacia has given an irrevocable undertaking to vote (i) in favour of the shareholder resolution at the first shareholder meeting to approve the Scheme, and (ii) against any alternative transaction (being a transaction in relation to Arix which is proposed by any person other than RTW Bio or which would otherwise hinder or impede the implementation of the Scheme), in respect of the Arix Shares it holds, which represent approximately 25.5 per cent of Arix's issued share capital.
RTW OpCo has given an irrevocable undertaking that, following and subject to completion of the Share Purchase, it will vote in favour of the shareholder resolutions relating to the Scheme at both shareholder meetings in respect of the Arix Shares it will hold, which will represent approximately 25.5 per cent of Arix's issued share capital.
The irrevocable undertakings referred to in this paragraph will cease to be binding if (i) the Scheme does not become effective on or before 23:59 (
Conditional appointment of RTW as investment manager
In connection with the above, Arix has entered into an investment management agreement (the "IMA") with RTW pursuant to which RTW will be appointed to manage the assets of Arix if the Scheme is not implemented. RTW will have sole responsibility for providing these portfolio management services, with discretion around the allocation and reallocation of Arix's resources among eligible investments.
The IMA will take effect in the event the Share Purchase has been completed but the Scheme is not approved by the Arix Shareholders. Further terms of the IMA (including details of fees payable to RTW Investments, LP) will be set out in the circular to be sent to Arix Shareholders in connection with the Scheme (the "Circular").
Completion of the Share Purchase
The Share Purchase is expected to complete in the first quarter of 2024. The sole condition to completion is FCA change of control approval.
Upon completion of the Share Purchase,
Arix has undertaken not to hold the second shareholder meeting to wind up Arix and appoint the liquidator until completion of the Share Purchase has occurred, save in certain limited circumstances.
Expected timetable
It is currently envisaged that the Circular and notice of the first general meeting setting out the details of the Scheme and seeking shareholder approval for the Scheme and liquidation will be sent to Arix's Shareholders in the fourth quarter of 2023, at the same time as the publication of a prospectus by RTW Bio in respect of the New RTW Bio Shares. The first Arix general meeting is expected to be held in early 2024.
A full timetable and further details of the Scheme will be set out in the Circular to be published by Arix in due course.
Analyst and investor presentation
Pre-recorded webinar
A pre-recorded webinar with RTW Bio's and Arix Biosciences' management teams is available in the Results and Presentations section of RTW Bio's website.
Investor Q&A call
There will be a live Q&A call with RTW Bio's management for institutional investors on Wednesday,
Sell-side analyst call
There will be a live presentation for sell-side analysts and sales teams on Wednesday,
Enquiries:
|
RTW Biotech Opportunities Ltd |
+44 20 7959 6361 |
|
Woody Stileman |
|
|
|
|
|
|
|
|
BofA Securities (Sole Financial Adviser & Joint Corporate Broker to RTW Bio) |
+44 20 7628 1000 |
|
|
|
|
|
|
|
Deutsche Numis (Joint Corporate Broker to RTW Bio) |
+44 20 7260 1000 |
|
|
|
|
|
|
|
Buchanan (PR & Communications adviser to RTW Bio) |
+44 20 7466 5107 |
|
Henry Wilson |
|
|
|
|
|
Cadarn Capital |
+44 7368 88321 |
|
|
|
|
|
|
|
Arix Bioscience plc |
+44 (0)20 7290 1050 |
|
|
|
|
Jefferies (Financial Adviser & Joint Corporate Broker to Arix) |
+44 20 7029 8000 |
|
|
|
|
|
|
|
|
|
|
Powerscourt Group (PR & Communications adviser to Arix) |
+44 20 7250 1446 |
|
|
|
|
|
|
|
|
|
|
|
|
Important information
Jefferies International Limited ("Jefferies"), which is authorised and regulated by the Financial Conduct Authority in the
Merrill Lynch International ("BofA Securities"), which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA in the
Numis Securities Limited (which is trading for these purposes as Deutsche Numis) ("Deutsche Numis"), which is authorised and regulated by the Financial Conduct Authority in the
Notice to US Shareholders in Arix
This announcement is not for publication or distribution, directly or indirectly, in or into
The New RTW Bio Shares will be offered and sold for investment purposes only in
RTW Bio is not registered, and does not intend to be subject to registration, as an investment company under the 1940 Act in reliance upon one or more exclusions or exemptions from registration thereunder.
The New RTW Bio Shares are subject to restrictions on transferability and resale and may not be transferred or resold except as permitted under the Securities Act, the 1940 Act and any applicable state and other securities laws, pursuant to registration or an exclusion or exemption therefrom. The transferability of the New RTW Bio Shares will be further restricted by the terms of the AI/QP Investor Letter, and any re-offer or resale of any New RTW Bio Shares in
Sources and Bases
1. The date two full business days before this announcement is
2. RTW BIO had 211,139,138 ordinary shares as at the Calculation Date.
3. RTW BIO VWAP of 1.1847 for the 30 day period to the Calculation Date.
4. GBP:USD FX rate of
5. GBP:USD FX rate of $1.2123 as at the Calculation Date.
6. Exchange ratio of 1.4633x based on offer price of
7. RTW BIO factsheet and quarterly letter for the period ending
8. RTW BIO half-year report for the period ending
9. Arix unaudited NAV for period ending
10. Arix interim results for the period ending
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE